The Australian company is now looking for partners with a positive interim analysis of data from the ACTION3 Phase 3 trial of DMX-200 in patients with a debilitating kidney disease. …
Dimerix's DMX-200 successfully passes interim analysis in ACTION3 Phase 3 trial
March 11, 2024 Australian Biotech
Latest Video
New Stories
-
Outcomes published from meeting the PBAC was directed to hold
June 22, 2025 - - Latest News -
TGA-licensed compounders call for review to ensure sustainability
June 20, 2025 - - Latest News -
GLP-1 pill study marks potential new chapter in treating diabetes and weight loss
June 20, 2025 - - Latest News -
An ideological darkness underpins our system's decision-making
June 20, 2025 - - Latest News -
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma